Tag: Genome Therapeutics Corp

icagen

Genome Therapeutics And ICAgen Collaborate To Conduct Drug Target Analysis

Genome Therapeutics Corp. and ICAgen, Inc. have announced an agreement that utilizes Genome Therapeutics’ technology to facilitate the assessment and development of a clinical trial design protocol for one of ICAgen’s ion channel targets. The genomics technology utilizes polymorphism analysis in subgroups of the target patient population to rapidly determine the target’s efficacy and thus Read more about Genome Therapeutics And ICAgen Collaborate To Conduct Drug Target Analysis[…]

anti-infective

ArQule And Genome Therapeutics Sign Anti-infective Agreement

ArQule, Inc. and Genome Therapeutics have announced a new drug discovery collaboration uniting their key strengths in the genomics and chemistry fields. ArQule will use their new Parallel Track Drug Discovery program to screen and optimise compounds against an expanded number of proprietary validated anti-infective targets which Genome Therapeutics has derived from its PathoGenome Database. Read more about ArQule And Genome Therapeutics Sign Anti-infective Agreement[…]